These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 38658986)

  • 21. Efficacy and safety of sodium-glucose cotransporter 2 inhibitors initiation in patients with acute heart failure, with and without type 2 diabetes: a systematic review and meta-analysis.
    Salah HM; Al'Aref SJ; Khan MS; Al-Hawwas M; Vallurupalli S; Mehta JL; Mounsey JP; Greene SJ; McGuire DK; Lopes RD; Fudim M
    Cardiovasc Diabetol; 2022 Feb; 21(1):20. PubMed ID: 35123480
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of sodium-glucose cotransporter-2 inhibitors on myocardial infarction incidence: A systematic review and meta-analysis of randomized controlled trials and cohort studies.
    Huang X; Dannya E; Liu X; Yu Y; Tian P; Li Z
    Diabetes Obes Metab; 2024 Mar; 26(3):1040-1049. PubMed ID: 38086546
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Influence of Sodium-Glucose Cotransporter-2 Inhibitors on Plasma Adiponectin in Patients with Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials.
    Wang Y; Xia N
    Horm Metab Res; 2022 Dec; 54(12):833-844. PubMed ID: 36049756
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Correlation of Osteoporosis in Patients With Newly Diagnosed Type 2 Diabetes: A Retrospective Study in Chinese Population.
    Wen Y; Li H; Zhang X; Liu P; Ma J; Zhang L; Zhang K; Song L
    Front Endocrinol (Lausanne); 2021; 12():531904. PubMed ID: 34054717
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of SGLT2 inhibitors on cardiac function and health status in chronic heart failure: a systematic review and meta-analysis.
    Chen J; Jiang C; Guo M; Zeng Y; Jiang Z; Zhang D; Tu M; Tan X; Yan P; Xu X; Long Y; Xu Y
    Cardiovasc Diabetol; 2024 Jan; 23(1):2. PubMed ID: 38172861
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Influence of type 2 diabetes microangiopathy on bone mineral density and bone metabolism: A meta-analysis.
    Zhao J; Liang G; Luo M; Yang W; Xu N; Luo M; Pan J; Liu J; Zeng L
    Heliyon; 2022 Oct; 8(10):e11001. PubMed ID: 36267364
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison between SGLT2 inhibitors and DPP4 inhibitors added to insulin therapy in type 2 diabetes: a systematic review with indirect comparison meta-analysis.
    Min SH; Yoon JH; Hahn S; Cho YM
    Diabetes Metab Res Rev; 2017 Jan; 33(1):. PubMed ID: 27155214
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin.
    Ljunggren Ö; Bolinder J; Johansson L; Wilding J; Langkilde AM; Sjöström CD; Sugg J; Parikh S
    Diabetes Obes Metab; 2012 Nov; 14(11):990-9. PubMed ID: 22651373
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lack of evidence for a harmful effect of sodium-glucose co-transporter 2 (SGLT2) inhibitors on fracture risk among type 2 diabetes patients: a network and cumulative meta-analysis of randomized controlled trials.
    Tang HL; Li DD; Zhang JJ; Hsu YH; Wang TS; Zhai SD; Song YQ
    Diabetes Obes Metab; 2016 Dec; 18(12):1199-1206. PubMed ID: 27407013
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on renal outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A protocol for systematic review and meta-analysis.
    Yu B; Dong C; Hu Z; Liu B
    Medicine (Baltimore); 2021 Feb; 100(8):e24655. PubMed ID: 33663074
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pancreatic safety of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes mellitus: A systematic review and meta-analysis.
    Tang H; Yang K; Li X; Song Y; Han J
    Pharmacoepidemiol Drug Saf; 2020 Feb; 29(2):161-172. PubMed ID: 32017292
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bexagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, for improvement of glycemia in type 2 diabetes mellitus: a systematic review and meta-analysis.
    Dholariya S; Dutta S; Singh R; Parchwani D; Sonagra A; Kaliya M
    Expert Opin Pharmacother; 2023; 24(18):2187-2198. PubMed ID: 37817422
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on mineral metabolism and bone in patients with type 2 diabetes mellitus.
    Alba M; Xie J; Fung A; Desai M
    Curr Med Res Opin; 2016 Aug; 32(8):1375-85. PubMed ID: 27046479
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association of Sodium-Glucose Cotransporter 2 Inhibitors With Cardiovascular Outcomes in Patients With Type 2 Diabetes and Other Risk Factors for Cardiovascular Disease: A Meta-analysis.
    Bhattarai M; Salih M; Regmi M; Al-Akchar M; Deshpande R; Niaz Z; Kulkarni A; Siddique M; Hegde S
    JAMA Netw Open; 2022 Jan; 5(1):e2142078. PubMed ID: 34985519
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of resveratrol supplementation on bone quality: a systematic review and meta-analysis of randomized controlled trials.
    Li Q; Yang G; Xu H; Tang S; Lee WY
    BMC Complement Med Ther; 2021 Aug; 21(1):214. PubMed ID: 34420523
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term renal outcomes associated with sodium glucose cotransporter 2 inhibitors in patients with type 2 diabetes mellitus: A systematic review and meta-analysis.
    Zhang X; Zhong Z; Li Y; Li W
    Diabetes Metab Res Rev; 2020 Jul; 36(5):e3303. PubMed ID: 32134558
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Elevated serum magnesium associated with SGLT2 inhibitor use in type 2 diabetes patients: a meta-analysis of randomised controlled trials.
    Tang H; Zhang X; Zhang J; Li Y; Del Gobbo LC; Zhai S; Song Y
    Diabetologia; 2016 Dec; 59(12):2546-2551. PubMed ID: 27628105
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical Adverse Events of High-Dose vs Low-Dose Sodium-Glucose Cotransporter 2 Inhibitors in Type 2 Diabetes: A Meta-Analysis of 51 Randomized Clinical Trials.
    Shi FH; Li H; Yue J; Jiang YH; Gu ZC; Ma J; Lin HW
    J Clin Endocrinol Metab; 2020 Nov; 105(11):. PubMed ID: 32841351
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of sodium-glucose co-transporter 2 inhibitors on hepatic parameters: A systematic review and meta-analysis of randomized controlled trials.
    Simental-Mendía M; Sánchez-García A; Rodríguez-Ramírez M; Simental-Mendía LE
    Pharmacol Res; 2021 Jan; 163():105319. PubMed ID: 33246172
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of sodium-glucose cotransporter-2 (SGLT2) inhibitors on serum urate levels in patients with and without diabetes: a systematic review and meta-regression of 43 randomized controlled trials.
    Yip ASY; Leong S; Teo YH; Teo YN; Syn NLX; See RM; Wee CF; Chong EY; Lee CH; Chan MY; Yeo TC; Wong RCC; Chai P; Sia CH
    Ther Adv Chronic Dis; 2022; 13():20406223221083509. PubMed ID: 35342538
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.